Study ranks safety, effectiveness of cognitive enhancers for Alzheimer's

September 29, 2017, St. Michael's Hospital
Dr. Andrea Tricco. Credit: St. Michael's Hospital

A new study ranking the safety and effectiveness of four drugs taken to enhance concentration, memory, alertness and moods, found that donepezil was most likely to effectively improve cognition in patients with Alzheimer's dementia.

However, patients who took donepezil were more likely to experience side effects including nausea, vomiting and diarrhea than those who received a placebo, according to the study, published online today in the Journal of the American Geriatrics Society.

In 2015, 46 million people worldwide had Alzheimer's disease, according to the study. In 2013, 146,593 people aged 65 and older in Ontario alone used cognitive enhancers, according to a 2016 Ontario Drug Policy Research report.

"Alzheimer's is the most common form of dementia in North America, and most people who have moderate to severe Alzheimer's will be on these medications," said Dr. Andrea Tricco, a scientist in the Li Ka Shing Knowledge Institute of St. Michael's Hospital and lead author of the study. "This analysis will give both patients and clinicians a full picture of how each of these drugs will likely affect their cognition, as well as their overall health."

Although there have been previous reviews of the safety and effectiveness of cognitive enhancers in treating Alzheimer's dementia, the authors said this was the first to rank their comparative safety and effectiveness.

The study used network meta-analysis, an advanced statistical analysis technique, to systematically review existing evidence from 142 of four common cognitive enhancers administered alone or in combination published between 1996 and 2015. The number of patients in each study ranged from 13 to 2,045, and the review evaluated a total of 33,889 patients.

The researchers compared the safety and effectiveness of any combination of donepezil, rivastigmine, galantamine or memantine in treating moderate to severe Alzheimer's dementia based on the results of the clinical trials that examined a number of patient outcomes, including cognition, function behaviour, global status, mortality, serious adverse events, falls, bradycardia, headache, diarrhea, vomiting and nausea. Donepezil was likely the most effective medication for Alzheimer's dementia across all effectiveness outcomes, including cognition, behavior and overall health, according to the study.

Donepezil was also the only enhancer that reached the minimal clinically important threshold—meaning effects on outcomes were observed clinically, as well as statistically—on the Alzheimer's Disease Assessment cognition scale, making it the likely first choice for those patients and clinicians considering these medications, the authors said.

Although no significant risk of serious harm, falls or reduced heart rate was associated with any of the medications in the study, the data was limited on these specific outcomes.

Previous research by the authors found that do not improve cognition or function in people with , and these patients experience significantly more nausea, diarrhea, vomiting and headaches.

The findings of the current study will help guide and clinicians who are making decisions about the best course of treatment for Alzheimer's dementia, said Dr. Tricco.

"The more information we are able to gather about how each of these medications can affect a patient's cognition and health, the more likely we are to be able to improve their health outcomes," she said.

Explore further: Cognitive enhancers don't improve cognition, function in people with mild cognitive impairment

Related Stories

Cognitive enhancers don't improve cognition, function in people with mild cognitive impairment

September 16, 2013
Cognitive enhancers—drugs taken to enhance concentration, memory, alertness and moods—do not improve cognition or function in people with mild cognitive impairment in the long term, according to a new study by researchers ...

Alzheimer's drug prescribed 'off-label' for mild cognitive impairment could pose risk for some

February 24, 2017
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that ...

Withdrawing dementia drug doubles risk of nursing home placement

October 27, 2015
Withdrawing a commonly-prescribed Alzheimer's disease drug from people in the advanced stages of the disease doubles their risk of being placed in a nursing home within a year, according to UCL research published today in ...

Commonly used dementia drugs can help more patients with Alzheimer's

March 7, 2012
The dementia drug donepezil (Aricept), already widely used to treat mild to moderate Alzheimer's disease, can also help in moderate to severe patients, according to a report funded by the UK Medical Research Council (MRC) ...

Extending use of existing Alzheimer's drug could delay move into nursing home

October 27, 2015
Newly-released follow-up analysis from a 2012 clinical trial led by a UK-based research team suggests that continuing treatment of the commonly-prescribed dementia drug donepezil into the later stages of Alzheimer's could ...

Recommended for you

What really causes Alzheimer's and how might we fix it?

May 23, 2018
There have been a lot of theories about what causes Alzheimer's disease. Many of them have given rise to experimental treatments of one form or another. None of them have worked much better than taking anything you might ...

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Moderate to high intensity exercise does not slow cognitive decline in people with dementia

May 16, 2018
Moderate to high intensity exercise does not slow cognitive (mental) impairment in older people with dementia, finds a trial published by The BMJ today.

Mutation discovered to protect against Alzheimer's disease in mice

May 16, 2018
Researchers at the RIKEN Center for Brain Science have discovered a mutation that can protect against Alzheimer's disease in mice. Published in the scientific journal Nature Communications, the study found that a specific ...

Most deprived are nearly twice as likely to develop dementia

May 16, 2018
Older adults in England with fewer financial resources are more likely to develop dementia, according to new UCL research.

Scientists discover a variation of the genome predisposing to Alzheimer's disease

May 15, 2018
An article published in Nature Medicine shows that the inheritance of small changes in DNA alters the expression of the PM20D1 gene and is associated with an increased risk of developing Alzheimer's disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.